Article

Dry eye trial enrollment complete

SARcode Bioscience Inc. has completed patient enrollment in its first pivotal phase III clinical study (OPUS-1) of SAR 1118 ophthalmic solution for dry eye disease.

Brisbane CA-SARcode Bioscience Inc. has completed patient enrollment in its first pivotal phase III clinical study (OPUS-1) of SAR 1118 ophthalmic solution for dry eye disease.

Also, the company announced that the solution has been given the nonproprietary name of lifitegrast via the Adopted Name Council and the World Health Organization’s International Nonproprietary Names program.

Lifitegrast is a first-in-class small-molecule integrin antagonist designed to inhibit T-cell inflammation by blocking the binding of two surface proteins (LFA-1 and ICAM-1) that mediate the chronic inflammatory cascade associated with dry eye disease. It was developed specifically for topical ophthalmic use.

OPUS-1 is a randomized, double-masked study evaluating the safety and efficacy of lifitegrast 5.0% ophthalmic solution compared with placebo over 12 weeks. A total of 588 patients with dry eye disease have been enrolled at 13 clinical sites across the United States.

The primary endpoints in this study will assess both a sign and a symptom of dry eye disease and will include corneal fluorescein staining score and vision-related function score (reading, driving at night, computer use, watching television) as measured by the Ocular Surface Disease Index.

“We look forward to the eventual analysis of the top-line data once OPUS-1 is completed,” said Charles Semba, MD, chief medical officer. Results should be announced mid-year, he added.

Quinton Oswald, the company’s chief executive officer, said, “We believe that lifitegrast will represent a significant advance in dry eye treatment, since it may address not only a clinical sign but also improve a patient’s ability to function in the face of this often debilitating condition.”

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.